Effect of four-week cannabidiol treatment on cognitive function: secondary outcomes from a randomised clinical trial for the treatment of cannabis use disorder

被引:12
|
作者
Lees, Rachel [1 ]
Hines, Lindsey A. A. [3 ]
Hindocha, Chandni [4 ]
Baio, Gianluca [5 ]
Shaban, Natacha D. C. [6 ]
Stothart, George [2 ]
Mofeez, Ali [7 ]
Morgan, Celia J. A. [8 ]
Curran, H. Valerie [4 ]
Freeman, Tom P. P. [1 ]
机构
[1] Univ Bath, Dept Psychol, Addict & Mental Hlth Grp, Bath, England
[2] Univ Bath, Dept Psychol, Bath, England
[3] Univ Bristol, Bristol Med Sch, Populat Hlth Sci, Bristol, England
[4] UCL, Clin Psychopharmacol Unit, London, England
[5] UCL, Dept Stat Sci, London, England
[6] Univ Oxford, Oxford, England
[7] UCLH, Natl Hosp Neurol & Neurosurg, Pain Management Ctr, London, England
[8] Univ Exeter, Psychopharmacol & Addict Res Ctr, Exeter, England
基金
英国医学研究理事会;
关键词
Cannabidiol; Cannabis use disorder; Clinical trial; Cognition; Verbal learning and memory; MEMORY; SYMPTOMS; INTERVENTION; CBD;
D O I
10.1007/s00213-022-06303-5
中图分类号
Q189 [神经科学];
学科分类号
071006 ;
摘要
Rationale:Chronic cannabis use is associated with impaired cognitive function. Evidence indicates cannabidiol (CBD) might be beneficial for treating cannabis use disorder. CBD may also have pro-cognitive effects; however, its effect on cognition in people with cannabis use disorder is currently unclear. Objectives:We aimed to assess whether a 4-week CBD treatment impacted cognitive function. We hypothesised that CBD treatment would improve cognition from baseline to week 4, compared to placebo. Methods:Cognition was assessed as a secondary outcome in a phase 2a randomised, double-blind, parallel-group and placebo-controlled clinical trial of 4-week daily 200 mg, 400 mg and 800 mg CBD for the treatment of cannabis use disorder. Participants had moderate or severe DSM-5 cannabis use disorder and intended to quit cannabis use. Our pre-registered primary cognitive outcome was delayed prose recall. Secondary cognitive outcomes were immediate prose recall, stop signal reaction time, trail-making task performance, verbal fluency and digit span. Results:Seventy participants were randomly assigned to placebo (n = 23), 400 mg CBD (n = 24) and 800 mg CBD (n = 23). A 200 mg group was eliminated from the trial because it was an inefficacious dose at interim analysis (n = 12) and was not analysed here. For the primary cognitive outcome, there was no effect of CBD compared to placebo, evidenced by a lack of dose-by-time interaction at 400 mg (0.46, 95%CIs: - 1.41, 2.54) and 800 mg (0.89, 95%CIs: - 0.99, 2.81). There was no effect of CBD compared to placebo on secondary cognitive outcomes, except backwards digit span which increased following 800 mg CBD (0.30, 95%CIs: 0.02, 0.58). Conclusions:In this clinical trial for cannabis use disorder, CBD did not influence delayed verbal memory. CBD did not have broad cognitive effects but 800 mg daily treatment may improve working memory manipulation.
引用
收藏
页码:337 / 346
页数:10
相关论文
共 37 条
  • [21] Efficacy of trial-based cognitive therapy, behavioral activation and treatment as usual in the treatment of major depressive disorder: preliminary findings from a randomized clinical trial
    Hemanny, Curt
    Carvalho, Clara
    Maia, Nina
    Reis, Daniela
    Botelho, Ana Cristina
    Bonavides, Dagoberto
    Seixas, Camila
    de Oliveira, Irismar Reis
    CNS SPECTRUMS, 2020, 25 (04) : 535 - 544
  • [22] A randomised controlled clinical trial on the additional effect of hypnosis in a comprehensive treatment programme for in-patients with conversion disorder of the motor type
    Moene, FC
    Spinhoven, P
    Hoogduin, KAL
    van Dyck, R
    PSYCHOTHERAPY AND PSYCHOSOMATICS, 2002, 71 (02) : 66 - 76
  • [23] A Cognitive Biotype of Depression and Symptoms, Behavior Measures, Neural Circuits, and Differential Treatment Outcomes: A Prespecified Secondary Analysis of a Randomized Clinical Trial
    Hack, Laura M.
    Tozzi, Leonardo
    Zenteno, Samantha
    Olmsted, Alisa M.
    Hilton, Rachel
    Jubeir, Jenna
    Korgaonkar, Mayuresh S.
    Schatzberg, Alan F.
    Yesavage, Jerome A.
    O'Hara, Ruth
    Williams, Leanne M.
    JAMA NETWORK OPEN, 2023, 6 (06) : E2318411
  • [24] US Veterans Show Improvements in Subjective but Not Objective Sleep following Treatment for Posttraumatic Stress Disorder: Secondary Analyses from a Randomised Controlled Trial
    Mathersul, Danielle C.
    Schulz-Heik, R. Jay
    Avery, Timothy J.
    Allende, Santiago
    Zeitzer, Jamie M.
    Bayley, Peter J.
    DEPRESSION AND ANXIETY, 2023, 2023
  • [25] Insights from individuals successfully recovered from cannabis use disorder: natural versus treatment-assisted recoveries and abstinent versus moderation outcomes
    Hodgins, David C.
    Stea, Jonathan N.
    ADDICTION SCIENCE & CLINICAL PRACTICE, 2018, 13
  • [26] Insights from individuals successfully recovered from cannabis use disorder: natural versus treatment-assisted recoveries and abstinent versus moderation outcomes
    David C. Hodgins
    Jonathan N. Stea
    Addiction Science & Clinical Practice, 13
  • [27] Cognitive behavioral therapy for suicide prevention among Veterans receiving substance use disorder treatment: Results from a randomized trial
    Ilgen, Mark A.
    Olson-Madden, Jennifer H.
    Price, Amanda
    Brenner, Lisa A.
    King, Cheryl A.
    Blow, Frederic C.
    JOURNAL OF PSYCHIATRIC RESEARCH, 2023, 168 : 344 - 352
  • [28] Clinical and economic outcomes of remotely delivered cognitive behaviour therapy versus treatment as usual for repeat unscheduled care users with severe health anxiety: a multicentre randomised controlled trial
    Morriss, Richard
    Patel, Shireen
    Malins, Sam
    Guo, Boliang
    Higton, Fred
    James, Marilyn
    Wu, Mengjun
    Brown, Paula
    Boycott, Naomi
    Kaylor-Hughes, Catherine
    Morris, Martin
    Rowley, Emma
    Simpson, Jayne
    Smart, David
    Stubley, Michelle
    Kai, Joe
    Tyrer, Helen
    BMC MEDICINE, 2019, 17 (1)
  • [29] Potential effect modifiers for treatment with chiropractic manipulation versus sham manipulation for recurrent headaches in children aged 7–14 years: development of and results from a secondary analysis of a randomised clinical trial
    Susanne Lynge
    Werner Vach
    Kristina Boe Dissing
    Lise Hestbaek
    Chiropractic & Manual Therapies, 31
  • [30] Potential effect modifiers for treatment with chiropractic manipulation versus sham manipulation for recurrent headaches in children aged 7-14 years: development of and results from a secondary analysis of a randomised clinical trial
    Lynge, Susanne
    Vach, Werner
    Dissing, Kristina Boe
    Hestbaek, Lise
    CHIROPRACTIC & MANUAL THERAPIES, 2023, 31 (01)